Gaping antitrust trap opens for pharma in EU as top court rules AstraZeneca "anticompetitive"
This article was originally published in SRA
Executive Summary
Pharmaceutical companies operating in the EU will in future need to take more care in assessing whether they are potentially in a dominant position and thus more open to antitrust action, following a judgment issued today by the Court of Justice of the European Union.